口腔医学研究 ›› 2024, Vol. 40 ›› Issue (3): 242-247.DOI: 10.13701/j.cnki.kqyxyj.2024.03.010

• 口腔肿瘤学研究 • 上一篇    下一篇

肿瘤间质比在口腔鳞状细胞癌患者预后评估中的价值分析

房敏健1, 刘亮1*, 邱若兰1, 曹伟1, 葛素云2, 柴大敏2   

  1. 1.蚌埠医学院第一附属医院口腔科 安徽 蚌埠 233004;
    2.蚌埠医学院第一附属医院病理科 安徽 蚌埠 233004
  • 收稿日期:2023-09-25 出版日期:2024-03-28 发布日期:2024-03-25
  • 通讯作者: * 刘亮,E-mail:ansen99@126.com
  • 作者简介:房敏健(1997~ ),男,山东淄博人,硕士在读,住院医师,主要从事口腔颌面外科相关研究。
  • 基金资助:
    2021年高校学科(专业)拔尖人才学术资助项目(编号:gxbjZD2021058)

Value Analysis of Tumor Stroma Ratio in Prognostic Evaluation of Oral Squamous Cell Carcinoma Patients

FANG Minjian1, LIU Liang1*, QIU Ruolan1, CAO Wei1, GE Suyun2, CHAI Damin2   

  1. 1. Department of Stomatology, Bengbu Medical College First Affiliated Hospital, Bengbu 233004, China;
    2. Department of Pathology, Bengbu Medical College First Affiliated Hospital, Bengbu 233004, China
  • Received:2023-09-25 Online:2024-03-28 Published:2024-03-25

摘要: 目的:分析肿瘤间质比(tumor-stroma ratio,TSR)在口腔鳞状细胞癌(oral squamous cell carcinoma,OSCC)患者预后中的价值。方法:收集2015年1月~2017年12月在蚌埠医学院第一附属医院接受根治性切除术的OSCC患者为研究对象,并收集临床及病理资料。TSR以50%为界限,将其分为高间质比组(≥50%)及低间质比组(<50%)。分析TSR和OSCC患者的无病生存期及总生存期之间的关系。结果:术后随访及临床资料完整的98例患者中,高间质比患者42例,低间质比患者56例。高间质比组OSCC患者的5年总生存率以及5年无病生存率分别为 31.0%(13/42)、26.2%(11/42); 低间质比组OSCC患者的5年总生存率以及5年无病生存率分别为 73.2%(41/56)、67.9%(38/56)。肿瘤发病部位与患者的5年总生存率(χ2=1.327,P=0.932)及5年无病生存率(χ2=3.113,P=0.683)无关;肿瘤临床分期、TSR与患者的5年总生存率5年无病生存率显著相关(P<0.001)。单因素COX分析结果显示,年龄、肿瘤T分期、淋巴结转移、TSR与OSCC患者总体生存率以及无病生存率有关。而通过多因素COX研究显示,肿瘤T分期、淋巴结转移以及TSR是影响OSCC患者总生存率与无病生存率的独立危险因素(P<0.05)。结论:TSR可作为OSCC患者术后预后的影响因素,可为OSCC患者术后辅助治疗方法的选择提供参考依据。

关键词: 肿瘤间质比, 口腔鳞状细胞癌, 预后, 生存率

Abstract: Objective: To evaluate the prognostic significance of tumor stromal ratio (TSR) in oral squamous cell carcinoma (OSCC) patients. Methods: Clinical and pathological data were gathered from OSCC patients who had radical resection at the First Affiliated Hospital of Bengbu Medical College between January 2015 and December 2017. Based on the percentage limit of 50%, TSR is split into two groups: high-TSR (≥50%) and low-TSR (<50%). The connection between tumor-stromal ratio and the overall and disease-free survival of patients with OSCC was examined. Results: Within 98 patients who had complete postoperative follow-up and clinical data, 42 patients had a high tumor-stromal ratio and 56 patients had a low TSR. The 5-year overall survival rate of OSCC patients in the high TSR group was 31.0% (13/42), and 5-year disease-free survival rate was 26.2% (11/42). On the other hand, the 5-year overall survival rate of OSCC patients in the low TSR group was 73.2% (41/56), and 5-year disease-free survival rate was 67.9% (38/56). Tumor clinical stage and TSR were substantially correlated with patients' 5-year overall survival and 5-year disease-free survival (P<0.001). Tumor site was not associated with patients' 5-year overall survival (χ2=1.327, P=0.932) and 5-year disease-free survival (χ2=3.113, P=0.683). Age, T staging, lymph node metastases, TSR, and OSCC disease-free survival rates were substantially connected with overall survival rates for patients with OSCC, according to single factor COX regression analysis results. Tumor T stage, lymph node metastasis, and tumor-stromal ratio were identified as independent risk variables for overall survival and disease-free survival in OSCC patients by multivariate COX analysis (P<0.05). Conclusion: Following surgery, TSR can be utilized as a prognostic indicator for OSCC patients and as a guide for the choice of adjuvant treatment options for OSCC patients.

Key words: tumor-stroma ratio, oral squamous cell carcinoma, prognosis, survival rate